China Meheco subsidiary's drug passes key evaluation

China Meheco Health Industry Co., Ltd. announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Lincomycin Hydrochloride Injection. The drug successfully passed the consistency evaluation for generic drug quality and efficacy, as per a notification issued on September 24, 2025.

Lincomycin Hydrochloride Injection, primarily used to treat severe infections caused by sensitive bacteria, represents a significant market opportunity. The project has incurred a cumulative investment of approximately CNY 6.08 million to date. While the original drug is not imported into China, 10 other domestic companies have also passed or are deemed to have passed the consistency evaluation for this drug.

According to third-party database statistics, domestic public hospital and primary care medical terminal sales of the drug in 2024 were approximately CNY 0.77 bn. Tianfang Pharmaceutical's sales of this drug in 2024 were approximately CNY 15.32 million. This approval is expected to boost the drug's market competitiveness and expand its share.